NOV 17, 202670 MINS READ
The oxidation of L-methionine to methionine sulfoxide occurs through the reaction of the thioether sulfur atom with reactive oxygen species (ROS) or other oxidizing agents 2. This process generates two diastereomeric forms: methionine-S-sulfoxide and methionine-R-sulfoxide, due to the creation of a chiral center at the sulfur atom 2. The formation of methionine sulfoxide in proteins can significantly alter their structural and functional properties, as the introduction of a polar sulfoxide group disrupts hydrophobic interactions and may affect protein folding 2,12.
Key oxidative pathways include:
The susceptibility of methionine to oxidation makes it function as an endogenous antioxidant in proteins, protecting more critical residues from oxidative damage 2. Research on methionylmethionine stereoisomers has revealed that oxidation products (mono- and di-sulfoxides, as well as sulfones) exhibit altered physicochemical properties, including increased water solubility and reduced odor compared to the parent compound 4. Specifically, the oxidation of D-methionyl-L-methionine, L-methionyl-D-methionine, and D-methionyl-D-methionine stereoisomers produces sulfoxides and sulfones with controllable solubility profiles depending on the oxidation stage 4.
Novel immunological methods have been developed for the specific detection of methionine sulfoxide residues in proteins 2. Antibodies recognizing methionine sulfoxide are generated by immunizing animals with modified proteins containing methionine sulfoxide residues, such as oxidized methionine-rich zein proteins 2. These antibodies enable:
The antibodies can be produced as monoclonal, polyclonal, or humanized forms in various animal systems, providing flexibility for different research and diagnostic applications 2.
Traditional chemical approaches exploit the differential reactivity of methionine versus methionine sulfoxide 12. Cyanogen bromide selectively reacts with methionine residues to form methyl cyanide but does not react with methionine sulfoxide 12. However, this method presents significant practical challenges:
These limitations have driven the development of alternative enzymatic and fluorescence-based detection methods 12.
Methionine sulfoxide reductase (MSR) enzymes provide the basis for sensitive enzymatic detection systems 12. The enzyme catalyzes the reduction of methionine sulfoxide back to methionine using reducing reagents such as thioredoxin or dithiothreitol (DTT) as electron donors 12. Novel fluorescently-labeled reducing agents bearing covalently-linked reporter tags enable quantification of methionine sulfoxide through measurement of oxidized reducing reagent formation, which is proportional to the methionine sulfoxide content in the sample 12. This approach offers advantages over radioactive methods previously employed, such as the radiolabeled acetyl methionine sulfoxide assay described by Brot et al. (1982) 12.
The biological reduction of methionine sulfoxide to methionine is catalyzed by methionine sulfoxide reductase enzymes, which play critical roles in cellular defense against oxidative stress 12. These enzymes utilize disulfide reducing reagents as substrates to provide reducing equivalents for the reaction 12. The MSR system demonstrates stereospecificity, with distinct enzyme forms (MsrA and MsrB) reducing the S- and R-diastereomers of methionine sulfoxide, respectively 2.
Key characteristics of MSR-catalyzed reactions include:
The development of MSR-based assays has enabled researchers to quantify methionine sulfoxide in protein samples by measuring the consumption of reducing equivalents or the production of reduced methionine 12. These enzymatic methods offer superior sensitivity and specificity compared to chemical approaches, particularly for complex biological samples 12.
Industrial production of L-methionine through biotechnological routes must account for potential oxidative modifications during synthesis and purification 1,5,8,9. Modern processes employ enzymatic reactions between L-methionine precursors (such as O-acetyl-L-homoserine) and sulfur-containing reagents like methyl mercaptan or dimethyl disulfide (DMDS) 1,5,8,9. During these multi-step syntheses, exposure to oxidizing conditions or residual oxidants can lead to methionine sulfoxide formation, reducing product yield and quality 1,9.
Key process considerations include:
The two-step biotechnological process described in patents involves first generating methyl mercaptan from DMDS through enzymatic reduction using hydrogen, catalytic amounts of thiol-bearing amino acids or peptides, and enzymes catalyzing disulfide bridge reduction 1,5,11. This methyl mercaptan then reacts with L-methionine precursors to form L-methionine 1,8,9. Throughout this process, maintaining reducing conditions is critical to prevent methionine sulfoxide formation 1,5.
Pharmaceutical and feed-grade L-methionine specifications typically include limits on oxidized impurities, including methionine sulfoxide 1,8. Analytical methods must be implemented to:
Research on methionylmethionine oxidation products has demonstrated that sulfoxides exhibit increased water solubility compared to the parent compound, which may affect formulation properties and bioavailability 4. This finding has implications for both quality control specifications and potential applications of controlled oxidation in product development 4.
Understanding methionine sulfoxide formation is critical for developing stable biopharmaceutical formulations, as oxidation of methionine residues in therapeutic proteins can lead to loss of activity, altered pharmacokinetics, or increased immunogenicity 2. Specific applications include:
The development of methionine sulfoxide-specific antibodies has enabled researchers to identify proteins showing increased methionine sulfoxide levels in disease states, facilitating biomarker discovery and validation 2. These tools are particularly valuable for studying oxidative stress-related diseases where protein oxidation plays a pathogenic role 2.
Oxidation products of methionylmethionine, including sulfoxides and sulfones, have found applications in cosmetic formulations for nail and hair treatment 4. Key advantages of these oxidized derivatives include:
Cosmetic formulations containing sulfoxides and sulfones of D-methionyl-L-methionine, L-methionyl-D-methionine, and D-methionyl-D-methionine stereoisomers have been developed for topical application 4. The controllable solubility achieved through different oxidation stages allows formulators to optimize product texture and delivery characteristics 4.
Methionine sulfoxide chemistry has enabled the development of novel analytical reagents and research tools 12. Fluorescently-labeled reducing agents bearing covalently-linked reporter tags provide sensitive methods for quantifying oxidation-reduction phenomena in proteins and peptides 12. These reagents offer advantages over traditional methods:
Kits incorporating these novel reagents, methionine sulfoxide reductase enzymes, and standardized protocols enable researchers to analyze methionine sulfoxide content in protein samples and assess disulfide linkages in polypeptides 12. These tools support studies in protein chemistry, oxidative stress biology, and pharmaceutical development 12.
The oxidation of methionine to methionine sulfoxide creates a chiral center at the sulfur atom, generating two diastereomeric forms (S- and R-sulfoxides) that exhibit distinct biological properties 2,4. This stereochemical complexity has important implications:
Studies on methionylmethionine stereoisomers (D-methionyl-L-methionine, L-methionyl-D-methionine, and D-methionyl-D-methionine) have revealed that oxidation can occur at either methionine residue, producing mono-sulfoxides, di-sulfoxides, and ultimately sulfones under strong oxidizing conditions 4. The specific oxidation pattern affects the physicochemical properties of the resulting compounds, including solubility, stability, and biological activity 4.
While distinct from methionine sulfoxide, L-methionine sulfoximine (MSO) represents another oxidized derivative of methionine with important biological activities 3,6,7. MSO is a potent inhibitor of glutamine synthetase and has been investigated for therapeutic applications in conditions involving glutamine metabolism dysregulation 3,6,7. Key differences between methionine sulfoxide and methionine sulfoximine include:
Research on MSO has established that only the L-methionine-S-sulfoximine stereoisomer inhibits glutamine synthetase and causes convulsions in animal models, demonstrating the importance of stereochemistry in biological activity 6,7. Novel dosage forms of L-methionine S-sulfoximine (≤10 mg/kg body weight over one week, preferably ≤2.5 mg/kg) have been developed to minimize convulsant side effects while maintaining therapeutic efficacy for treating hyperammonemic encephalopathy 3,6,7.
Biotechnological L-methionine production processes can be optimized to minimize methionine sulfoxide formation through careful control of reaction conditions 1,5,8,9:
The use of enzymes from specific bacterial sources can also influence oxidation susceptibility. For example, O-acetylhomoserine sulfohydrylase from Corynebacterium humireducens and mutants thereof have been employed in L-methionine synthesis, with enzyme selection affecting both conversion efficiency and product purity 8. Similarly, improved variants such as MetZ_Rsp_I3N_F65Y_V104A from Rhodobacter sphaeroides offer enhanced conversion rates and shortened reaction times, potentially reducing oxidative exposure 8.
Proper handling of L-methionine precursors and intermediates is essential for preventing oxidation 1,5,8,9:
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| UNIVERSITY OF KANSAS | Diagnostic testing for oxidative protein damage in clinical specimens, biomarker discovery for neurodegenerative diseases, and screening oxidative stress-related pathologies. | Methionine Sulfoxide Antibody Kit | Antibodies specifically recognize methionine sulfoxide residues in proteins, enabling identification of oxidatively damaged proteins in neurodegenerative diseases and oxidative stress conditions. |
| ARKEMA FRANCE | Industrial biotechnological production of pharmaceutical and feed-grade L-methionine with reduced oxidative impurities and improved product purity. | Enzymatic L-Methionine Production System | Two-step enzymatic process converts dimethyl disulfide (DMDS) to methyl mercaptan then to L-methionine, minimizing oxidative side reactions and methionine sulfoxide formation through controlled reducing conditions. |
| EVONIK OPERATIONS GMBH | Cosmetic formulations for nail and hair treatment requiring improved solubility, reduced odor, and enhanced aesthetic properties. | Methionylmethionine Sulfoxide Derivatives | Oxidized methionylmethionine products (sulfoxides and sulfones) exhibit increased water solubility, odorless properties, and colorless appearance compared to parent compound. |
| PROMEGA CORPORATION | Protein quality control in biopharmaceutical development, oxidative stress research, and analysis of disulfide linkages in peptides and proteins. | Fluorescent Methionine Sulfoxide Detection Kit | Fluorescently-labeled reducing agents with covalently-linked reporter tags enable quantification of methionine sulfoxide through methionine sulfoxide reductase enzymatic assay, eliminating toxic reagents like cyanogen bromide. |
| MSO PHARMA LLC | Treatment of progressive hyperammonemic encephalopathy and cerebral edema in patients with glutamine metabolism disorders. | L-Methionine S-Sulfoximine Low-Dose Formulation | Novel dosage form (≤10 mg/kg body weight per week) inhibits glutamine synthetase without convulsant side effects, reducing brain swelling in hyperammonemic conditions. |